throbber
0021-972X/85/6103-0536$02.00/0
`Journal of Clinical Endocrinology and Metabolism
`Copyright© 1985 by The Endocrine Society
`
`Vol.6l, No 3
`Printed in U.s.A.
`
`Successful Treatment of Cushing's Syndrome with the
`Glucocorticoid Antagonist RU 486*
`
`LYNNETTE K. NIEMAN, GEORGE P. CHROUSOS, CHARLES KELLNER,
`IRVING M. SPITZ, BRUCE C. NISULA, GORDON B. CUTLER,
`GEORGE R. MERRIAM, C. WAYNE BARDIN, AND D. LYNN LORIAUX
`Developmental Endocrinology Branch, N ational Institute of Child Health and Human Development (L.K.N.,
`G.P.C., B. C.N., G.B.C., G.R.M., D.L.L.); the Biological Psychiatry Branch, National Institute of Mental
`Health (C.K), National Institutes of Health, Bethesda, Maryland 20205; and the Population Council (!.M.S .,
`C. W. B.), New York, New York 00000
`
`ABSTRACT. A patient with Cushing's syndrome due to ec(cid:173)
`topic ACTH secretion was treated successfully with the new
`glucocorticoid antagonist RU 486 (17{j-hydroxy-ll{j-(4-dimeth(cid:173)
`ylamino phenyl) 17 a-(1-propynyl)estra-4,9-dien-3-one ]. This
`compound is a 19-nor steroid with substitutions at positions Cll
`and C17 which antagonizes cortisol action competitively at the
`receptor leveL Oral RU 486 was given in increasin g doses of 5,
`10,15, and 20 mg/kg ·day for a 9-week period. T reatment eficacy
`was monitored by assessment of clinical status and by measu.ri ng
`several glucocorticoid-sensitive variables, including fasting blood
`sugar, blood sugar 120 min after oral glucose administration,
`
`and plasma concentrations of TSH, corticosteroid-binding glob(cid:173)
`ulin, LH, testosterone-estradiol-binding globulin, and total and
`free testosterone. With therapy, the somatic features of Cush(cid:173)
`ing's syndrome (buffalo hump, central obesity, and moon faci e.~)
`ameliorated, mean arterial blood pres ure normalized, suicidal
`depression resolved, and libido re~ed. AU biochemical gluco(cid:173)
`corticoid-sensitive parameters normalized. No side-effects of
`drug toxicity were observed. We conclude that RU 486 may
`provide a safe, well tolerated, and effective medical treatment
`for hypercortisolism. (J Clin Endocrinol Metab 61: 536, 1985)
`
`T HE CURRENTLY available treatments for Cush(cid:173)
`
`ing's syndrome caused by metastatic ACTH-pro(cid:173)
`ducing tumors or adrenal cancer are often unsatisfactory.
`Surgical resection of the tumor, when feasible, may be
`only partially or temporarily effective in controlling
`Cushing's syndrome. Medical therapy with adrenolytic
`agents (o,p '-DDD) or steroidogenic enzyme inhibitors
`(aminoglutethimide or metyrapone) is frequentiy asso(cid:173)
`ciated with toxic side-effects (1-5).
`A clinically applicable glucocorticoid antagonist is, in
`theory, an attractive alternative treatment for hypercor(cid:173)
`tisolism and has been sought for many years (6). The
`recently discovered compound RU 486 [17,8-hydroxy-
`11,8-(4-dimethylamino phenyl) 17 a-(1-propynyl)estra-
`4,9-dien-3-one], a 19-rtor steroid with a high affinity for
`the rat glucocorticoid receptor with no agonist effects in
`vitro or in vivo, is a potent competitive glucocorticoid
`antagonist in rodents (7), nonhuman primates (8, 9), and
`man (10-12).
`
`Received March 15, 1985.
`Address requests for reprints to: Dr. Nieman, National Institutes of
`Health, Building 10, Room 10N262, Bethesda, Maryland 20205.
`* Presented in part at ·the Seventh International Congress of Endo(cid:173)
`crinology, Quebec, Canada, July 1984.
`
`536
`
`We report here the successful treatment with RU 486
`of a 25-yr-old man with Cushing's syndrome caused by
`the ectopic secretion of ACTH. During therapy, the
`somatic features of Cushing's syndrome (cervical fat pad,
`central obesity, and moon facies) improved, suicidal
`depression cleared, and glucocorticoid-sensitive meas(cid:173)
`ures, such as elevated fasting and postabsorptive blood
`sugar, normalized. The drug was tolerated well, and rto
`side-effects were noted during therapy or after its discon(cid:173)
`tinuation.
`
`Case Report
`The patient was in excellent health until the fall of 1981
`when he noted· loss of strength, short term memory, and atten(cid:173)
`tion span. In the spring of 1982, because these symptoms
`worsened, he discontinued his weight-lifting regimen. He com·
`plained of increasing anxiety and depression. In September
`1982, he stopped workjng because of these cognitive and psy(cid:173)
`chological changes. Treat ment with antidepressants was initi(cid:173)
`ated. His depression deepened, however, and led to two suicide
`attempts. At that time, he had moon fac ies, hypertension, and
`diabetes, and was evaluated for Cushing's syndrome. Both
`serum and Uiinary cortisol levels were elevated, and 17-hydroJ·
`ycorticosteroid excretion increased during a standard 2- and 8.·
`mg dexamet hasone suppression test (13).
`.
`An intrathoracic mass lesion was found and was resected 111
`
`1
`
`TEVA1012
`
`

`

`ANTIGLUCOCORTICOID THERAPY
`
`537
`
`A.
`GIUCOM 2 Hr OGTT (mg/dl)
`
`B.
`LH(miU/ml)
`
`230
`
`Feeling GIUCOM (mg/dl)
`
`TeBG (~g/dl)
`
`CBG(~g/dl)
`
`FrM Teetoeterone (ng/dl)
`28
`
`NJarch i983. The lesion was not contiguous with a bronchus.
`~[icroscopic and immunohistochemical examination of the
`speci men showed a carcinoid tumor with granules that stained
`with anti-ACTH serum. Immediately after surgery, plasma
`cortisol levels were normal. Insulin and antihypertensive and
`011 tidepressant medications were discontinued, and the pa(cid:173)
`tient's symptoms improved. By May 1983, however, his symp(cid:173)
`toms recurred, and his urinary cortisol excretion rate was about
`500 !Lg/day. He was given metyrapone, but had only transient
`clinical improvement.
`In August 19.83, he was admitted to the NIH. He complained
`of disorientation, diminished memory and cognitive ability,
`impotence, a 20-lb weight gain over 3 yr, and long-standing
`!lluscle weakness. He had a ruddy round face. His blood pres(cid:173)
`sure was 180/120 mm Hg, and his pulse was 90 beats/min. He
`was anxious and depressed. He performed calculations slowly.
`The thoracotomy scar was hyperpigmented. Computerized axial
`tomogra.ms of the chest revealed multiple lung nodules. He had
`hypokalemic alkalosis (serum potassium, 1.9 meqfliter; bicar(cid:173)
`bonate, 38 meq/ liter; chloride, 94 meqfliter; sodium, 147 meqf
`liter).
`His medications, including maprotiline hydrochloride (Lu(cid:173)
`diomil), trifloroperazine (Stelazine), benztropin mesylate (Co(cid:173)
`gentin), and metyrapone (1 g/day) were stopped before labo(cid:173)
`ratory evaluation. H e became withdrawn, severely depressed,
`and complained that he felt unable to think clearly. Ludiomil
`was reinitiated because of suicidal ideation, and his depressive
`symptoms and cognition improved. Potassium supplements
`were given (20-120 meqfday}. Treatment with increasing doses
`of RU 486 for 9 weeks caused marked improvement in all
`biochemical and clinical parameters of hypercortisolism (see
`Results).
`
`Materials and Methods
`
`Protocol
`
`The protocol for the therapeutic use of RU 486 was approved
`under an investigational exemption for new drugs by the Na(cid:173)
`tional Center for Drugs and Biologics, DHHS, and by the
`NICHHD Clinical Research Committee (83-CH-87). The pa(cid:173)
`tient participated in the study after giving informed consent.
`All tests were performed at the NIH Clinical Center.
`RU 486 was formulated into 50-mg tablets by Roussel(cid:173)
`UCLAF (Paris, France) . A single oral dose of 6 mg/kg RU 486
`given at midnight has been found to prevent morning adrenal
`suppression caused by 1 r:ng dexamethasone (11). Accordingly,
`the initial oral daily dose was 5 mg/kg and increased in 5 mg/
`kg increments every 1 or 2 weeks to a maximum of 20 mg/kg ·
`day (see Fig. 1).
`A number of clinical and biochemical glucocorticoid-sensi(cid:173)
`tive measures were monitored to evaluate treatment efficacy.
`Clinical :r;neasures included blood pressure and body Weight.
`The patient's mood was assessed daily by a self-report ques(cid:173)
`tionnaire and three times a week by psychiatric interviews (14).
`Metabolic and hormone measures included urinary excretion
`of nitrogen and fasting and postabsorptive blood sugar, which
`are elevated by hypercortisolism, and plasma concentrations of
`corticosteroid-binding globulin (CBG) (15), testosterone-astra-
`
`Dose RU 486 (mg/kg/d)
`
`~~F
`
`I ~ I
`
`15
`
`45
`
`DoM RU 486 (mg/kg/d)
`
`~~F I ~.
`
`45
`
`75
`
`15
`75
`DAY OF ADIII.SSION
`FIG. 1. The effect of RU 486 treatment on glucocorticoid-sensitive
`variables. A, Two hour post-OGTT (oral glucose tolerance test) and
`fasting blood sugar levels were elevated before RU 486 therapy and fell
`to normal levels during treatment. The serum TSH concentration was
`initially subnormal and rose progressively. CBG concentrations also
`rose into the normal rarige. Mean daily blood pressure decreased during
`RU 486 therapy. B, Plasma concentrations of LH, total testosterone,
`and free testosterone were initally depressed; all normalized with RU
`486 therapy. TeBG capacity showed similar increases. Shaded areas
`represent the upper (L..L..UJ) or l9wer (LLLJ) normal range.
`
`dial-binding globulin (TeBG), testosterone (16, 17), LH (16,
`17), and TSH (18, 19), which are suppressed by hypercortisol(cid:173)
`ism.
`Plasma ACTH and plasma and urinary cortjsol levels also
`were measured frequently. Metabolic and hormonal measure(cid:173)
`ments were made on one to three morning blood samples drawn
`before therapy and during the final week of each dose interval.
`Standard oral glucose tolerance tests were performed after 3
`days of ingestion of a 100-g carbohydrate diet using a 100-g
`glucose challenge. Creatinine, blood urea nitrogen (BUN)
`serum glutamic o:X:aloacetic acid-transaminase (SGOT), and
`serum glutamic pyruvic acid-transaminase (SGPT) measure(cid:173)
`ments were monitored throughout treatment as indices of drug
`toxicity. Serial electrocardiograms and chest x-rays were done
`for a similar purpose.
`
`2
`
`

`

`538
`
`Assays
`
`NIEMAN ET AL.
`
`Plasma testosterone (20), LH (21), ACTH (22), steroid bio(cid:173)
`synthetic intermediates (pregnenolone, 17-hydroxypregneno(cid:173)
`lone, 17-hydroxyprogesterone, and 11-deoxycortisol) (20, 23),
`plasma and urinary cortisol (23), and serum TSH (24) were
`measured by RIA as previously described. CBG and TeBG were
`measured using a solid phase Concanavalin A-Sepharose assay
`(25). The free testosterone concentration was calculated from
`the measured levels of total hormone and binding proteins
`(albumin and TeBG) (25). Plasma glucose concentrations were
`measured with a Cobas bioanalyzer; SGOT, SGPT, BUN, cre(cid:173)
`atinine and albumin concentrations were measured with an
`Autoanalyzer (Beckman, Palo Alto, CA).
`Using a previously described method for separation of bound
`from free hormone (25), competitive binding assays were done
`to exclude displacement by RU 486 of testosterone or cortisol
`from their plasma binding proteins, an action that might result
`in spurious <:hanges in hormone concentrations. Increasing
`concentrations of RU 486 or unlabled hormone were added to
`samples with known amounts of radioactively labeled hormone
`and binding globulin. RU 486 did hot displace cortisol from
`CBG or testosterone from TeBG in concentrations ranging
`from 10-10-10-5 M.
`
`Results
`
`All glucocorticoid-sensitive clinical and biochemical
`parameters were initially abnormal in this patient, and
`each became normal during treatment with RU 486
`despite continued marked hypercortisolism.
`The physical stigmata of Cushing's syndrome, includ(cid:173)
`ing supraclavicular and dorsocervical fat pads and central
`obesity, regressed considerably by the conclusion of ther(cid:173)
`apy. This change in fat distribution was not associated,
`however, with a change in total body weight, which varied
`between 85 and 89 kg both before and during RU 486
`treatment. Maximum daily systolic and diastolic blood
`pressures decreased steadily during treatment with RU
`486, from 200/120 mm Hg before therapy, to 140/90 mm
`Hg at its conclusion (Fig. lA). The hypokalemic alkalosis
`resolved, serum potassium ranged from 3.9-4.6 meq/liter,
`and serum bicarbonate ranged from 25-29 meq/liter
`following discontinuation of potassium after the sixth
`week of RU 486 therapy.
`Both subjective and objective psychological measures
`improved during RU 486 therapy. When the daily dose
`of RU 486 was increased to 15 mg/kg, Ludiomil therapy
`was stopped (fourth week of therapy). The patient's
`depression continued to improve, and he reported in(cid:173)
`creasing attention span, libido, and sense of wellbeing.
`This subjective improvement was corroborated by self(cid:173)
`rating questionnaires and psychiatric interviews.
`Plasma glucose levels were initially 140 mg/dl in the
`fasting state (normal, <105 mg/dl) and 268 mg/dl 2 h
`after ingestion of 100 g glucose (normal, <140 mg/dl; Fig.
`lA). The fasting blood sugar level became normal while
`
`the patient was taking RU 486 in a dose of 10 mg/kg.
`day, and the 2 b postoral glucose tolerance test blood
`sugar level normalized when be was taking 20 mgjk
`(Fig. lA). Serum TSH concentration was initially sub~
`normal. ( <0.18 IL U /ml) and rose progressively to 1.5 J.LU;
`ml durmg treatment (normal, 0.5-4.5 .uU/ml; Fig. lA).
`CBG-binding capacity increased from 7.4 ,ug/dl (normal
`12.2- 20 ,ug/dl) to 16.8 J.Lg/ dl (Fig. 1B).
`'
`Plasma LH levels rose during treatment with RU 486
`from 9.4 to 23.2 miU/ml (normal, 6-26 miU/ml; Fig.
`lB). Similarly, plasma total and free testosterone con(cid:173)
`centrations and TeBG-binding capacity increased from
`subnormal to normal levels during therapy with RU 486
`(Fig. lB). The total testosterone concentration was ini(cid:173)
`t ially 73 ng/ dl (normal, 200-1000 ng/dl) and rose to 842
`ng/dl when the patient was taking 20 mg/kg.day RU
`486. TeBG capacity increased from 0.063 J.Lg/dl normal;
`0.2-1.0 J.Lg/dl) to 1.02 ,ug/dl at the conclusion of therapy:
`Free testosterone increased from 3.5 ng/dl (normal, 5-
`30 ng/dl) to 17.4 ng/dl.
`Twenty-four hour urinary nitrogen excretion fell from
`22 gjday (normal, 12-20 g/day) before treatment to 5 g/
`day at its conclusion. No abnormalities in serum creati(cid:173)
`nine, BUN, SGOT, or 'sGPT, urinalysis, electrocardi(cid:173)
`ogram, chest radiography, or physical examination were
`found during or after therapy. The patient experienced
`,
`no adverse subjective effects.
`In contrast to the marked improvement in these glu(cid:173)
`cocorticoid-sensitive parameters, urinary cortisol,
`plasma cortisol, and ACTH levels remained significantly
`elevated throughout the treatment with RU 486. G-50
`gel chromatography revealed that 85% of ACTH immu(cid:173)
`noreactivity was in the same fractions as ACTH -(1-39).
`Before initiation ofRU therapy, the mean plasma ACTH
`concentration was 165 ± 7.6 (±SE) pg/ml (n = 5); during
`treatment, it was 241 ± 14 pg/ml (n = 14; normal, 8-15
`pg/ml). The range of plasma cortisol-concentration was
`29-49.5 J.Lg/dl (mean ± SE, 43.5 ± 3.3 J.Lg/dl; n = 7) before
`and 13.8-56.5 J.Lg/dl (mean ± SE, 31.8 ± 2.0 J.Lg/dl; n,;
`27) during RU 486 administration (normal, 8-18 J.Lg/dl).
`Mean daily urinary cortisol excretion rates also were
`elevated, ranging between 514 and 11,592 J.Lg/day (mean
`± SE, 4865 ± 1159 J.Lg/24 h; n = 11) before theraPY·
`During therapy, urinary cortisol excretion was similar
`and ranged between 106 and 8072 J.Lg/day (mean ± sE,
`1175 ± 327 J.Lg/24 h; n = 27; normal, 20-95 J.Lg/24 h).
`Plasma steroid precursor concentrations during ther(cid:173)
`apy were within the normal range or mildly elevated(cid:173)
`Pregnenolone was 124 ng/dl (normal, <250), 17-hydrol·
`ypregnenolone was 135 ng/dl (normal, <250), 17-hydrol·
`yprogesterone was 706 ng/dl (normal, <200), and 11-
`deoxycorlisol was 431 ng/dl (normal, <200).
`No side-effects occurred during RU 486 treatment. 1~
`the lOth week, because limited availability of RU 48
`
`3
`
`

`

`ANTIGLUCOCORTICOID THERAPY
`
`539
`
`reve11ted further treatment, the patient underwent a
`~jlateral adren~lectomy 48 h after disco~ti:~mation of
`therapy and durmg supplemental glucocortlc01d therapy.
`tfissue vascularity was normal at the time of surgery,
`~nd his postoperative course and wound healing were
`sfltisfactory.
`
`Discussion
`
`The glucocorticoid antagonist RU 486 ameliorated the
`clinical and biochemical features of hypercortisolism in
`thi - patient. Treatment with RU 486 was associated with
`redistribution of body fat and resolution of severe depres(cid:173)
`sion, hyperglycemia, and hypertension, obviating the
`need for a variety of medications which he previously
`required. Several hormonal disorders typical of hyper(cid:173)
`cortisolism (suppressed plasma levels of TSH, LH, tes(cid:173)
`tos erone, CBG, and TeBG) also reverted to normal
`during RU 486 therapy (15, 19).
`The satisfactory response to RU 486 administration
`despite persistent marked elevation of serum and urinary
`cortisol levels is consistent with studies of its mechanism
`of action in vitro and in animals. RU 486 interacts with
`the glucocorticoid receptor and thereby blocks the effects
`of cortisol (7). The mild decline in plasma and urinary
`cor isol during therapy might be due to an additional
`effect of RU 486 to diminish adrenal steroidogenesis
`directly via enzyme inhibition or a result of spontaneous
`fluctuation in the severity of the syndrome. No major
`block occurred, however, in the enzymes 3{3-hydroxyste(cid:173)
`roid dehydrogenase-115,.14-isomerase,21-hydroxylase, 17-
`hydroxylase, or 11-pydroxylase, as suggested from the
`levels of measured steroid precursors in the patient's
`plasma.
`Although RU 486 was an effective therapy in our
`patient with Cushing's syndrome due to ectopic ACTH
`secretion, control may be more difficult to achieve in
`patients with hypercortisolism of pituitary origin (Cush(cid:173)
`ing's disease). Previous studies in nonhuman primates
`and normal subjects suggest that the dose of RU 486
`necessary to achieve normal glucocorticoid status in
`Cushing's syndrome will depend on the plasma free cor(cid:173)
`tisol concentration and the presence of cortisol feedback.
`In nonhuman primates and normal men and women,
`doses of RU 486 greater than 5 mg/kg cause an increase
`in both plasma cortisol and ACTH levels, presumably by
`antagonizing cortisol feedback at the pituitary or hypo(cid:173)
`thalamus (8-12). In patients with Cushing's disease in
`whom cortisol feedback is present, ACTH levels may
`increase, perhaps in an exaggerated manner, as is often
`the case with ACTH responses to CRH (22) or metyra(cid:173)
`pone (26). Nevertheless, high doses of a glucocorticoid
`antagonist may overcome the reserve of the pituitary
`adrenal axis in patients with Cushing's disease and thus
`
`alleviate the toxic effects of hypercorticolism on tissues.
`If this were true, then an antiglucocorticoid could be used
`for preparation of patients for surgery.
`The lack of side-effects or toxicity associated with RU
`486 administration in our patient contrasts markedly
`with the morbidity that characterizes the other medical
`treatments for hypercortisolism. Although the incidence
`of side-effects cannot be established until additional
`patients are studied, the present experience suggests that
`RU 486 therapy may be tolerated better than other
`currently available medical treatments of hypercortisol(cid:173)
`ism. Greater tolerance may yield greater efficacy, since
`the available medical treatments often cannot be given
`in fully effective doses because of their side-effects.
`One potential problem with RU 486 is that overtreat(cid:173)
`ment might cause glucocorticoid insufficiency. Since glu(cid:173)
`cocorticoid insufficiency cannot be assessed through
`measurement of adrenal steroids during RU 486 therapy,
`we suggest that patients be given RU 486 in gradually
`increasing doses in concert with careful evaluation for
`signs and symptoms of adrenal insufficiency.
`Currently, the major drawback of RU 486 is that it is
`costly to synthesize and not available in quantities suf(cid:173)
`ficient for extensive clinical study. Despite these prob(cid:173)
`lems, RU 486 holds promise as a safe, well tolerated, and
`effective medical therapy for hypercortisolism that mer(cid:173)
`its further clinical evaluation.
`
`Acknowledgments
`
`We would like to thank Ms. Penny Colbert, Mary Hall, and Mary
`Beth McCole for their assistance in typing this manuscript.
`
`References
`1. Temple TE, Liddle GW 1970 Inhibitors of adrenal steroid biosyn(cid:173)
`thesis. Annu Rev Pharmacol10:199
`2. Carey RM, Orth DN, Hartmann WH 1973 Malignant melanoma
`with ectopic production of adrenocorticotropic hormone: palliative
`treatment with inhibitors of adrenal steroid biosynthesis. J Clin
`Endocrinol Metab 36:482
`3. Gordon P, Becker CE, Levey GS, Roth J 1968 Efficacy of amino(cid:173)
`glutethimide in the ectopic ACTH syndrome. J Clin Endocrinol
`Metab 28:921
`4. Col! R, Horner I, Kraiem Z, Gafni J 1968 Successful metyrapone
`therapy of the ectopic ACTH syndrome. Arch Intern Med 121:549
`5. Gold EM 1979 The Cushing syndrome: changing views of diagnosis
`and treatment. Ann Intern Med 90:829
`6. Chrousos GP, Cutler Jr GB, Sauer M, Simons Jr SS, Loriaux DL
`1983 Development of glucocorticoid antagonists. Pharmacol Ther
`20:263
`7. Philibert D, Deraedt R, Teutsch G, RU 38486 a potent antigluco(cid:173)
`corticoid in vivo. International Congress of Pharmacology, Tokyo,
`Japan, 1981, p 668 (Abstract)
`8. Healy DL, Chrousos GP, Schulte HM, Williams RF, Baulieu EE,
`Gold PW, Hodgen GD 1983 Pituitary and adrenal responses to the
`anti-progesterone and anti-glucocorticoid steroid RU 486 in pri(cid:173)
`mates. J Clin Endocrinol Metab 57:863
`9. Healy DL, Chrousos GP, Schulte HM, Gold PW, and Hodgen GD
`1985 Increased ACTH, cortisol and arginine vasopressin (A VP)
`secretion following the antiglucocorticoid RU 486: dose-response
`relationships. J Clin Endocrinol Metab 60:1
`
`4
`
`

`

`540
`
`NIEMAN ET AL.
`
`JCE& M•19ll5
`Vol6l•Noa
`
`10. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz
`E 1982 Effet d'un steroide anti-progesterone chez Ia femme: inter(cid:173)
`ruption da cycle menstruel et de la grossesse au debut. C R Acad
`Sci [D] (Paris) 294:933
`11. Gaillard RC, Riondel A, Herrmann W, Muller AF, Baulieu EE,
`The antifertility steroid RU 486 is an anticorticosteroid derepress(cid:173)
`ing the pituitary-adrenal system in the human, bot only at a specific
`time during the day. 65th Annual Meeting ofthe Endocrine Society,
`San Antonio TX, 1983, p 219 (Abstract)
`12. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F 1984
`The new steroid analog RU 486 inhibits glucocorticoid action in
`man. J Olin Endocrinol Metab 59:25
`13. Liddle GW 1960 Tests of pituitary-adrenal suppressibility in the
`diagnosis of Cushing's syndrome. JOlin Endocrinol Metab 20:1539
`14. Spielberger CD, Corsuch RL, Lushene RE 1970 State-Trait Anxi(cid:173)
`ety Inventory (STAI) Manual. Consulting Psychologists Press,
`Palo Alto
`15. Nieman LK, Chrousos GP, Schulte HM, Loriaux DL, Nisula BC,
`Adrenal re.gulation of corticosteroid-binding globulin (CBG). 7th
`International Congress of Endocrinology, Quebec, Canada, 1984
`Excerpt Med lnt Congr Ser 652:1096 (Abstract 16'72)
`16. Smals AGH, Kloppenborg PWC, Benraad T J 1977 Plasma testos(cid:173)
`terone profiles in Cushing's syndrome. J Clin Endocrinol Metab
`45:240
`17. Luton J-P, Thieblot P, Valke J-C, Mahoudeau JA, Bricaire H 1977
`Reversible gonadotropin deficiency in male Cushing's disease. J
`Olin Endocrinol Metab 45:488
`
`18. Van Cauter E, Leclercq R, Vanhaelst L, Golstein J 1974 Simulta.
`neous study of cortisol and TSH daily variations in normal subjects
`and patients with hype:r:adrenalcorticism. J Olin Endocrinol Metab
`39:64_5
`19. Duick DS, Wahner HW 1979 Thyroid axis in patients with Cush(cid:173)
`ing's syndrome. Arch Intern Med 139:767
`20. Abraham GE 1974 Radioimmunoassay of steroids in bioloboical
`materials. Acta Endocrinol [Suppll83] (Copenh) 75:7
`21. Odell WD, Ros GR, Rayford PL 1966 Radioimmunoassay of
`human luteinizing hormone. Metab Olin Eltp 15:287
`22. Chrousos GP, chulte HM, Oldfield EH, Gold PW, Cutler GB
`Loriaux DL 1984 The corticotropin-releasing factor stimulatio~
`test: an aid in the evaluation of patients with Cushing s syndrome.
`N Eng! J Med 310:622
`23. Kao M, Voina S, Nichols A, Horton R 1975 Parallel radioimmu(cid:173)
`noassay for plasma cortisol and 11-deoxycortisol. Olin Chern
`21:1644
`24. Wehmann RE, Rubenstein BA, Nisula BC 1979 A sensitive con(cid:173)
`venient radioimmunoassay procedure which demonstrate~ that
`serum hTSH is suppressed below the normal range in thyrotoxjc
`patients. Endocr Res Commun 6:249
`25. Dunn JF, Nisula BC, Rodbard D 1981 Transport of steroid hor(cid:173)
`mones: binding of 21 endogenous ste.roids to both testosterone(cid:173)
`binding globulin and corticosteroid-binding globulin in human
`plasma. J Olin Endocrinol Metab 53:58
`26. Tucci JR 1975 Metyrapone test in Cushing's disease. J Clin En(cid:173)
`docrinol Metab 40:520
`
`5
`
`

`

`
`
`.>
`
`I
`III’)
`n
`‘
`,‘
`
`,
`
`)
`I
`.
`fw'
`
`.
`
`‘
`
`,
`
`g
`‘_
`
`‘
`
`1
`1
`l‘
`
`‘
`
`1..
`
`,
`
`.
`J.
`
`v'
`
`'5§
`.
` ,:
`M'
`
`7
`
`CLINIC L
`NDOCRINOLO
`GMETABOLIS
`
`.
`
`1“
`
`volume 61/l‘lumber 3/SEPTEMBER 1985
`JCEMAZ/ISSN 0021-972)!
`
`g i I
`
`SSUED MONTHLY FOR
`THE ENDOCRINE SOCIETY
`
`6
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket